The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Recognizing the urgent need for treatment options and guided by patient insights, Pfizer scientists have discovered a way to ...

Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...